We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00225797
Recruitment Status : Completed
First Posted : September 26, 2005
Last Update Posted : February 15, 2010
Information provided by:
Endo Pharmaceuticals

Brief Summary:
The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in non-cancer patients with chronic low back pain.

Condition or disease Intervention/treatment Phase
Chronic Pain Drug: Oxymorphone Extended Release Phase 3

Detailed Description:
Patients with low back pain who are sub-optimally responsive to their current analgesic treatment begin open-label treatment with oxymorphone extended release (ER). During the Open-Label Titration Period, patients will receive daily oxymorphone ER by mouth (PO) q12h. The investigator will initiate the Open-Label Titration Period using study drug at a dose of 5 mg PO q12h for 2 days; thereafter, patients will continue receiving 5 mg q12h or be titrated at increments of 5-10 mg q12h every 3-7 days until stabilization is achieved. The goal of the Open-Label Titration Period is to determine for each patient a fixed dose of study medication that is tolerated and achieves adequate analgesia. Stabilized patients will be randomiozed to either continue with current dose of oxymorphone ER or receive placebo for a total duration of 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Naïve Patients With Chronic Low Back Pain
Study Start Date : November 2004
Study Completion Date : July 2005

Primary Outcome Measures :
  1. Change in pain intensity from baseline (pre-randomization) to last assessment.

Secondary Outcome Measures :
  1. Time to early discontinuation due to lack of efficacy
  2. Patient's Global Assessment of Pain Medication
  3. Physician's Global Assessment of Pain Medication
  4. Safety as measured by AEs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females 18 years of age or older
  • opioid naïve
  • Have an initial pain intensity score of at least 50 mm VAS
  • In good health as determined by the investigator on the basis of medical history and physical examination
  • Have moderate to severe chronic non-neuropathic LBP that has been present daily for at least several hours per day for a minimum of three months prior to the Screening
  • Any adjunct therapy for back pain such as physical therapy, biofeedback therapy, acupuncture therapy or herbal remedies, based on the patient's current status should remain unchanged during the period of participation of the patient
  • Written informed consent

Exclusion Criteria:

  • Pregnant and/or lactating
  • Radiculopathy, fibromyalgia, reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, severe lower extremity weakness or numbness, bowel or bladder dysfunction secondary to cauda equina compression, diabetic amyotrophy, meningitis, discitis, or back pain due to secondary infection or tumor
  • Cannot or will not agree to stop local regional pain treatments during the study (nerve/plexus blocks or ablation, neurosurgical procedures for pain control, or inhalation analgesia). The patient must not have a nerve/plexus block within 4 weeks of screening
  • Intend to alter physical therapy regimen during the study.
  • Surgical procedures directed towards the source of back pain within 6 months of screening
  • Pain which is secondary to confirmed or suspected neoplasm
  • Dysphagia or difficulty swallowing tablets or capsules, or an inability to take oral medication
  • Significant prior history of substance abuse or alcohol abuse
  • Use of any investigational medication within 30 days prior to the first dose of study medication
  • Previous exposure to oxymorphone
  • History of clinically significant intolerance to oxymorphone or a known hypersensitivity to opioid analgesics
  • History of seizure
  • Ileostomy or colostomy
  • Use of MAO inhibitor within 14 days prior to the start of study medication
  • Other clinically significant conditions as judged by the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00225797

Show Show 33 study locations
Sponsors and Collaborators
Endo Pharmaceuticals
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sr. Director Clinical R&D
ClinicalTrials.gov Identifier: NCT00225797    
Other Study ID Numbers: EN3202-031
First Posted: September 26, 2005    Key Record Dates
Last Update Posted: February 15, 2010
Last Verified: February 2010
Keywords provided by Endo Pharmaceuticals:
chronic pain
lower back
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Pain
Neurologic Manifestations
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia